NCT03661086View on ClinicalTrials.gov

Oxygen Control and Weaning by O2matic to Patients Admitted With an Exacerbation of COPD

NACompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
COPD ExacerbationHypoxiaHypoxemiaHyperoxiaRespiratory FailureRespiratory InsufficiencyCopd Exacerbation Acute
Interventions
DEVICE

O2matic

O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula

Trial Locations (5)

2400

Bispebjerg University Hospital, Copenhagen

2650

Hvidovre University Hospital, Hvidovre

2730

Herlev University Hospital, Herlev

2900

Gentofte University Hospital, Hellerup

3600

Nordsjællands Hospital, Frederikssund

Sponsors

Collaborators (1)

Innovation Fund Denmark
All Listed Sponsors
collaborator

Innovation Fund Denmark

INDIV

lead

Hvidovre University Hospital

OTHER